Bibliography
- Trikudanathan G, Dasanu CA. Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma. Expert Opin Pharmacother 2010;11:695-1704
- Raghav K, Overman MJ. Small bowel adenocarcinomas-existing evidence and evolving paradigms. Nat Rev Clin Oncol 2013;10:534-44
- Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004;101:518-26
- Moon YW, Rha SY, Shin SJ, et al. Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol 2010;136:387-94
- Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment and survival over the last 20 years. Ann Surg 2009;249:63-71
- Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 2010;21:1786-93
- Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis 2013. [ Epub ahead of print]
- Barnes G Jr, Romero L, Hess KR, et al. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol 1994;1:73-8
- Overman MJ. Rare but real: management of small bowel adenocarcinoma. Am Soc Clin Oncol Educ Book 2013;33:189-93
- Kelsey CR, Nelson JW, Willett CG, et al. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemotherapy. Int J Radiat Oncol Biol Phys 2007;69:1436-41
- Onkendi EO, Boostrom SY, Sarr MG, et al. Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy. J Gastrointest Surg 2012;16:320-4
- Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10 year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol) 2007;19:143-9
- Overman MJ, Kopetz S, Wen S, et al. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 2008;113:2038-45
- Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009;27:2598-603
- Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs 2012;23:561-6
- McWilliams RR, Mahoney MR, Marchello BT, et al. Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small bowel adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) trial (abstract). J Clin Oncol 2012;30(Suppl 4):a314
- Zaanan A, Gauthier M, Malka D, et al. Second Line Chemotherapy with Fluorouracil, Leucovorin and Irinotecan (FOLFIRI Regimen) in patients with advanced small bowel adenocarcinoma after failure of first line platinum based chemotherapy a multicenter AGEO study. Cancer 2011;117:1422-8
- Locher C, Malka D, Boige V, et al. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 2005;69:290-4
- Chang DK, Jamieson NB, Johns AL, et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of Vater. J Clin Oncol 2013;31:1348-56
- Tsushima T, Taguri M, Honma Y, et al. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist 2012;17:1163-70